| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 560 | 2021 |
| Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis WJ Magnuson, NH Lester-Coll, AJ Wu, TJ Yang, NA Lockney, NK Gerber, ... J Clin Oncol 35 (10), 1070-1077, 2017 | 451 | 2017 |
| The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib T Patil, DE Smith, PA Bunn, DL Aisner, AT Le, M Hancock, WT Purcell, ... Journal of Thoracic Oncology 13 (11), 1717-1726, 2018 | 148 | 2018 |
| NCCN guidelines® insights: non–small cell lung cancer, version 2.2023: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 21 (4), 340-350, 2023 | 113 | 2023 |
| Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene … TL Ng, Y Liu, A Dimou, T Patil, DL Aisner, Z Dong, T Jiang, C Su, C Wu, ... Cancer 125 (7), 1038-1049, 2019 | 77 | 2019 |
| On the ontological assumptions of the medical model of psychiatry: philosophical considerations and pragmatic tasks T Patil, J Giordano Philosophy, Ethics, and Humanities in Medicine 5, 1-7, 2010 | 73 | 2010 |
| ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboembolic events TL Ng, DE Smith, R Mushtaq, T Patil, A Dimou, S Yang, Q Liu, X Li, ... Journal of Thoracic Oncology 14 (4), 596-605, 2019 | 64 | 2019 |
| Baseline and on-treatment characteristics of serum tumor markers in stage IV oncogene-addicted adenocarcinoma of the lung SA Noonan, T Patil, D Gao, GG King, JR Thibault, X Lu, PA Bunn, ... Journal of Thoracic Oncology 13 (1), 134-138, 2018 | 62 | 2018 |
| Brain metastases in EGFR-and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation NJ Thomas, NJ Myall, F Sun, T Patil, R Mushtaq, C Yu, S Sinha, ... Journal of Thoracic Oncology 17 (1), 116-129, 2022 | 57 | 2022 |
| Long-term efficacy and safety of entrectinib in ROS1 fusion–positive NSCLC A Drilon, CH Chiu, Y Fan, BC Cho, S Lu, MJ Ahn, MG Krebs, SV Liu, ... JTO Clinical and Research Reports 3 (6), 100332, 2022 | 44 | 2022 |
| Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non–small-cell lung cancer T Patil, R Mushtaq, S Marsh, C Azelby, M Pujara, KD Davies, DL Aisner, ... Clinical lung cancer 21 (3), e191-e204, 2020 | 33 | 2020 |
| CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. DR Carrizosa, ME Burkard, YY Elamin, J Desai, SM Gadgeel, JJ Lin, ... Journal of Clinical Oncology 40 (16_suppl), 3006-3006, 2022 | 26 | 2022 |
| NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry. M Duruisseaux, SV Liu, JY Han, V Gounant, JY Shih, AM Schram, ... Journal of Clinical Oncology 37 (15_suppl), 9081-9081, 2019 | 26 | 2019 |
| Complications of androgen deprivation therapy in men with prostate cancer. T Patil, B Bernard Oncology (08909091) 32 (9), 2018 | 26 | 2018 |
| A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer NJ Gurule, CE McCoach, TK Hinz, DT Merrick, A Van Bokhoven, J Kim, ... NPJ precision oncology 5 (1), 41, 2021 | 24 | 2021 |
| Targeted therapies for ROS1-rearranged non-small cell lung cancer. T Patil, E Simons, R Mushtaq, JM Pacheco, RC Doebele, DW Bowles Drugs of Today (Barcelona, Spain: 1998) 55 (10), 641-652, 2019 | 24 | 2019 |
| Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status T Patil, DL Aisner, SA Noonan, PA Bunn, WT Purcell, LL Carr, ... Lung Cancer 96, 27-32, 2016 | 23 | 2016 |
| Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers NJ Choudhury, JL Schneider, T Patil, VW Zhu, DA Goldman, SR Yang, ... JTO Clinical and Research Reports 2 (7), 100187, 2021 | 22 | 2021 |
| Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers X Le, C Baik, J Bauman, J Gilbert, MS Brose, JE Grilley-Olson, T Patil, ... The Oncologist, oyac080, 2022 | 21 | 2022 |
| 2020 innovation‐based optimism for lung cancer outcomes EL Schenk, T Patil, J Pacheco, PA Bunn Jr The oncologist 26 (3), e454-e472, 2021 | 21 | 2021 |
